Abstract:Abstract Glycosylation and its products are crucial in clinical routines but are overshadowed by a framework embedding genomic participants in cancer development. The glycosylation scheme varies between research groups, presenting clinical concerns that demand understanding in cancer research beyond the glycome. Our work aims (a) to enhance the canonical framework by identifying potential glycosylation-associated genes (glycogenes) and (b) to advance translational cancer study, offering a unified perspective on integrative omics and explainable machine learning with glycogene integration. The expansion of the glycosylation framework involved initial text mining from curated databases like OMIM, InterPro, and Reactome. Dysregulation of identified genes was affirmed across 29 TCGA solid cancers, encompassing over 7,000 patients with primary tumors. And healthy tissue data from GTEx facilitated tumor-normal comparisons. Subsequently, integrative omic analysis, involving transcriptome and methylome, was applied to confirm the stratification feasibility of glycogenes and to revealed cancer clusters within the UMAP space. After cluster discovery, profiling from survival analysis and drug response prediction highlighted clinical differences between clusters. Employing a survival forest model and explainable artificial intelligence (XAI), personalized assessments, including a 5-year survival predictor and risk factors for individuals, were developed. Our study verified over 3,000 glycogenes, expanding the conventional configuration of glycosylation and constituting 10-30% of differentially expressed genes between tumors and healthy tissues. Whether transcriptome or methylome alone, glycogenes demonstrated stratification ability. Advanced omic integration further discovered 16 cancer clusters out of 29 TCGA cancers, associated with anatomical source, morphology, and genomic similarity. Utilizing drug resources from GDSC, this specialized geneset exhibited drug predicting ability, displaying a distinct drug response profile among the 16 clusters. To finalize the clinical potential, a survival forest for 5-year survival model construction concluded forecasters with a time-dependent AUC (0.77 to 0.92 on average) for each cancer cluster. With XAI implementation, survival risk factors were developed and assessed for each individual locally. Here we identified over 3,000 glycogenes, elaborating the classic glycosylation structure and emphasizing genomic importance in cancer research. Glycogenes demonstrated translational potential, supported by diverse survival distributions and drug responses across cancer clusters discovered by the integrative omic approach. The integration of XAI provided a tailored perspective for implementing glycogenes in clinical cancer research. Citation Format: Yen-Hsieh Chen, Yuh-Shan Jou. Systematic identification and clinical implications of glycogenes in cancer research: An integrative omics approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6215.

Glycosylation editing: an innovative therapeutic opportunity in precision oncology

Glycosylation in the Tumor Immune Response: the Bitter Side of Sweetness

Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy

Altered glycosylation in cancer: molecular functions and therapeutic potential

The Glycosylation of Immune Checkpoints and Their Applications in Oncology

Aberrant Glycosylation And Cancer Biomarker Discovery: A Promising And Thorny Journey

Progress of Proteomics Driven Precision Medicine-From a Glycosylation View.

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Thermally Triggered, Cell-Specific Enzymatic Glyco-Editing: <i>In Situ</i> Regulation of Lectin Recognition and Immune Response on Target Cells

Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications

Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics

CD44 Glycosylation as a Therapeutic Target in Oncology

Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy

Glycosylation in cancer as a source of biomarkers

Abstract 6215: Systematic identification and clinical implications of glycogenes in cancer research: An integrative omics approach

Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks

Advances in Glycosylation-Mediated Cancer-Targeted Drug Delivery.

Specifically Editing Cancer Sialoglycans for Enhanced Immunotherapy In Vivo through Aptamer‐Enzyme Chimeras

Glycosylation in cancer: mechanisms and clinical implications

Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma

Status Quo of Glycosylation in Cancer: What Is, What Is Not and What Is to Be